Gardner, MA December 10, 2009 -- New England Peptide (NEP) today announced the introduction of a proprietary peptide synthesis instrument, PepScale™, to better enable peptide scale-up and process development projects for its customers. The instrument is optimized for tens of grams and compliments NEP’s existing production capabilities. It was designed to provide the flexibility required for development work while taking advantage of the process efficiencies for which NEP has become known.
“At NEP, we pride ourselves at being a leader in peptide synthesis innovation,” said Ben Robinson, NEP’s Chief Operating Officer. “This proprietary instrument is a continued testament to our ability to create new products to meet our customers’ demands.”
At NEP, we pride ourselves at being a leader in peptide synthesis innovation,” said Ben Robinson, NEP’s Chief Operating Officer. “This proprietary instrument is a continued testament to our ability to create new products to meet our customers’ demands. The PepScale™ instrument was custom designed and built by NEP and incorporates the company’s chemistry knowledge at both a research and preclinical level. Based on the input of NEP’s highly experienced research and development team, NEP’s engineers designed the instrument to incorporate efficiencies and productivity that would benefit projects in early stage clinical development and API scale-up. PepScale's™ use of automation enables cost and time efficiencies to be realized when compared to manual synthesis, and also minimizes opportunities for human error.
The PepScale™ instrument, combined with the NEP development team’s extensive experience, helps customers work seamlessly with NEP from research and discovery through early stage development, including preclinical efforts. It provides a flexible option for manufacturing and scale-up that can better cover the range of preclinical peptide API needs of their customers.
PepScale™ is the latest in a line of proprietary product and process innovations created by NEP’s in-house development team. In July, NEP unveiled FlashPure™, the peptide industry’s first flash purification system. In September, NEP rolled out PepCRO™, the first peptide-focused contract research service for drug, vaccine and diagnostic discovery projects.
Customers interested in scaling up their peptide production should contact the NEP’s business development group at 888-343-5974.
About New England Peptide - NEP:
NEP, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.
Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides’ inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use.
